News
Three of the health secretary’s picks to replace fired members of an influential panel that sets U.S. vaccine policies have ...
Health Secretary Robert F. Kennedy Jr. named eight new members to the CDC’s Advisory Committee on Immunization Practices on ...
The Dow Jones Industrial Average (DJINDICES: ^DJI) index edged 3.9% higher in May, with 70% of its 30 constituent stocks ...
11h
News-Medical.Net on MSNBenchling and Merck collaborate on vaccine bioanalysisBenchling announced a new collaboration with Merck, known as MSD outside of the United States and Canada, to implement a ...
22h
Stocktwits on MSNMerck Gets FDA Approval For Keytruda To Treat A Broader Population Of Head And Neck Cancer Patients: Retail Stays BullishMerck (MRK) on Friday said that the U.S. Food and Drug Administration (FDA) has approved its blockbuster drug Keytruda for ...
Staff who provide data to the vaccine panel have been pushed aside, according to health officials, raising doubts about the ...
Among the eight people who Robert F. Kennedy Jr. announced would make up his new group of outside vaccine advisers to the US Centers for Disease Control and Prevention are an emergency physician who ...
Merck's Keytruda receives FDA approval for head and neck cancer after showing improved event-free survival in Phase 3 KEYNOTE ...
During a Community Case Forum event, Adil Daud, MD, discussed immunotherapy options for cutaneous squamous cell carcinoma.
Keytruda marks the first perioperative anti-PD-1 treatment option for adults with PD-L1–positive resectable locally advanced ...
Ravindra Uppaluri, MD, PhD, discusses the background regarding locally advanced head and neck cancer and what the trial design of KEYNOTE-689 entailed.
Keytruda was approved for locally advanced head and neck cancer before and after surgery, showing improved event-free ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results